← All trials
NCT03526588
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2018
- Primary completion
- Nov 1, 2027
- Completion date
- Nov 1, 2027
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Texas at HoustonLead sponsor
- University of Texas at HoustonReponsible party - principal investigator
- University of Texas at HoustonOverall official - principal investigator
- Texas Medical Center Regenerative Medicine ConsortiumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.